[Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies].

The ¹⁸F 2-fluoro-2-deoxyglucose (FDG) PET/CT scan is an imaging modality used in the management of patients with various types of malignancies. ¹⁸F-FDG PET/CT has demonstrated significant efficacy in the staging and detection of metastatic disease in malignancies of the gastrointestinal tract. The assessment of the metabolic response to chemotherapy and improvements of overall survivals in malignancies of esophagus and stomach has been demonstrated in several studies. This review focuses on the role of ¹⁸F-FDG PET/CT scan in staging, metastasis, predict of recurrence and assessment of metabolic response in malignancies of the upper gastrointestinal tract.

[1]  M. Schwaiger,et al.  Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis , 2007, Journal of Nuclear Medicine.

[2]  H. Katoh,et al.  Evaluation of 18F-2-deoxy-2-fluoro-d-glucose Positron Emission Tomography for Gastric Cancer , 2004, World Journal of Surgery.

[3]  J. Takita,et al.  The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma , 2005, Cancer.

[4]  P. Dupont,et al.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Bang,et al.  The role of PET/CT in detection of gastric cancer recurrence , 2009, BMC Cancer.

[6]  K. Kang,et al.  Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Lin Chen,et al.  The value of vesicant 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in gastric malignancies , 2004, Nuclear medicine communications.

[9]  D. Visvikis,et al.  Use of Positron Emission Tomography in Surgery Follow-Up of Esophageal Cancer , 2009, Journal of Gastrointestinal Surgery.

[10]  P. Conti,et al.  Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. , 2003, Clinical radiology.

[11]  Manish A Shah,et al.  Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. , 2011, World journal of gastroenterology.

[12]  A. Patriti,et al.  [Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC]. , 2007, Annali italiani di chirurgia.

[13]  H. Groen,et al.  Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Woo Jin Hyung,et al.  Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography , 2005, Cancer.

[16]  M. Schwaiger,et al.  FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  S. Larson,et al.  Accuracy of FDG-PET in Gastric Cancer. Preliminary Experience. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[18]  Y. Nishiyama,et al.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[20]  김주희,et al.  Comparison of CT and 18F-FDG PET for Detecting Peritoneal Metastasis on the Preoperative Evaluation for Gastric Carcinoma , 2006 .

[21]  Zheng Fu,et al.  Diagnostic and Prognostic Value of 18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus , 2007, Journal of Nuclear Medicine.

[22]  P. Bartenstein,et al.  Positron Emission Tomography for Staging Esophageal Cancer: Does It Lead to a Different Therapeutic Approach? , 2003, World Journal of Surgery.

[23]  S. Fanti,et al.  The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab , 2007, Gastric Cancer.

[24]  J. Lee,et al.  Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Isozaki,et al.  Usefulness of preoperative FDG-PET for detection of gastric cancer , 2006, Gastric Cancer.

[26]  T. Saga,et al.  Positron emission tomography for the diagnosis and management of patients with gastrointestinal malignancies. , 2008, Gastrointestinal endoscopy clinics of North America.

[27]  J. Shirlaw.  THE METABOLISM OF TUMOURS , 1931 .

[28]  H. Furukawa,et al.  Is PET-CT suitable for predicting lymph node status for gastric cancer? , 2008, Hepato-gastroenterology.

[29]  H. Fukuda,et al.  Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  V. Lowe,et al.  Comparison of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasound in the Initial Staging of Patients with Esophageal Cancer , 2005, Molecular Imaging and Biology.